Bioray Biotech Co., Ltd

As of June 30, 2026, Bioray Biotech Co., Ltd carries a market capitalization of 534.01M, placing it among publicly traded companies globally. Its enterprise value stands at 395.78M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bioray Biotech Co., Ltd has 29.59M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Bioray Biotech Co., Ltd maintains a current ratio of 4.73, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Bioray Biotech Co., Ltd's stock has declined approximately 27.10% over the past 52 weeks. The 50-day moving average sits at 19.06, while the 200-day moving average is 20.53.

As of June 30, 2026, Bioray Biotech Co., Ltd holds 209.21M in cash and equivalents against 70.98M in total debt, resulting in a net debt position of -109.21M. Total book value stands at 431.07M, with working capital of 259.94M providing operational flexibility.

Bioray Biotech Co., Ltd's most recent stock split took place on July 28, 2022 with a 196:201 split ratio.